Emerging Health Care Innovation Brief: Two Potential Treatments for Early Alzheimer’s Disease
About Us
- About PCORI
- The PCORI Strategic Plan
- Governance
- Evaluating Our Work
- PCORI's Advisory Panels
- Procurement Opportunities
-
Provide Input
-
Past Opportunities to Provide Input
- Stakeholder Views on Components of 'Patient-Centered Value' in Health and Health Care (2023)
- PCORI's Proposed Research Agenda (2021-2022)
- Proposed National Priorities for Health (2021)
- Proposed Principles for the Consideration of the Full Range of Outcomes Data in PCORI-Funded Research (2020)
- Proposed New PCORI Methodology Standards (2018)
- Data Access and Data Sharing Policy: Public Comment (2017)
- Proposed New PCORI Methodology Standards (2017)
-
Comment on the Proposed New and Revised PCORI Methodology Standards (2016)
- 1. Standards for Formulating Research Questions
- 10: Standards for Studies of Diagnostic Tests
- 12. Standards on Research Designs Using Clusters
- 13: General Comments on the Proposed Revisions to the PCORI Methodology Standards
- 2: Standards Associated with Patient-Centeredness
- 3: Standards for Data Integrity and Rigorous Analysis
- 4: Standards for Preventing and Handling Missing Data
- 5: Standards for Heterogeneity of Treatment Effects
- 6: Standards for Data Registries
- 7: Standards for Data Networks as Research-Facilitating Structures
- 8. Standards for Causal Inference Methods
- 9. Standards for Adaptive Trial Designs
- Peer-Review Process Comments (2014)
- Draft Methodology Report Public Comment Period (2012)
-
Past Opportunities to Provide Input
- Leadership
Image
The latest Emerging Health Care Innovation Brief highlights two potential treatments for early Alzheimer’s Disease (AD), the most common cause of dementia. It also causes declining cognitive function and the inability to perform activities of daily living.
The first experimental treatment, donanemab, is a humanized monoclonal antibody designed to bind amyloid-beta (Aβ) plaques and promote their clearance. It is intended to slow cognitive decline in patients with early AD.
The second experimental treatment, valiltramiprosate (ALZ-801), is an oral prodrug metabolized into tramiprosate, a compound that reportedly inhibits Aβ aggregation, thought to contribute to AD pathology.
This PCORI Emerging Health Care Innovation Brief is part of a series highlighting important topics of interest identified during the ongoing scanning and topic identification process or through a stakeholder survey process.
Useful Links
Tags
Recent Posts
What's Happening at PCORI?
The Patient-Centered Outcomes Research Institute sends weekly emails about opportunities to apply for funding, newly funded research studies and engagement projects, results of our funded research, webinars, and other new information posted on our site.
Image
